Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma

Acute encephalopathy secondary to dabrafenib and trametinib in BRAF-positive metastatic adenocarcinoma of the lung

“…There are a few case reports of posterior PRES induced by vemurafenib and cobimetinib. 3,9 However, the acute encephalopathy due to dabrafenib/trametinib appears to have distinctive mechanism. The high-grade fever appears to be more associated with the latter and not commonly seen with PRES.…”

“…There are a few case reports of encephalopathy in metastatic melanoma patients with BRAF and MEK inhibition. 3,4 Posterior reversible encephalopathy syndrome (PRES) has been previously described in literature as an adverse effect due to vemurafenib and cobimetinib in metastatic melanoma. 3 The patient provided verbal consent (to all authors) to use specific details in a de-identified manner to describe the acute event.…”

Posteriores reversibles Enzephalopathie‐Syndrom bei einem Melanompatienten unter Dabrafenib‐ und Trametinib‐Behandlung nach Immuntherapie

“…Nach unserem besten Wissen gibt es nur vier Fallberichte, in denen ein PRES durch eine der neuen Melanomtherapien ausgelöst wurde [8][9][10][11]. Jedoch wurde die Diagnose PRES in all diesen Fällen nicht hinlänglich gesichert, da unter anderem keine MRT durchgeführt wurden [8,10].…”

Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy

“…To the best of our knowledge, there are only four case reports on PRES under novel melanoma treatments [8][9][10][11]. However, the diagnosis of PRES in these cases was not completely reliable because an MRI was not performed [8,10].…”